Advances in Early Detection and Risk Stratification of Hepatocellular Carcinoma
Speaker: Jorge Marrero, MD — Chief, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania
Conference: INETS Session | 2025
1. Main Clinical Topics Discussed
- Global and U.S. epidemiology of hepatocellular carcinoma (HCC)
- Etiology-based risk stratification and surveillance population identification
- Performance of current surveillance tools (ultrasound + AFP)
- Impact of viral hepatitis treatment (DAA therapy, SVR) on HCC risk
- Evolution of HCC diagnostic criteria (LI-RADS)
- Evidence base for HCC surveillance programs and their impact on survival
2. Key Learning Points, Guidelines, and Recommendations
Surveillance Populations (per updated AASLD guidelines):
- All patients with cirrhosis of any etiology who are transplant candidates (Child-Pugh A/B)
- Non-cirrhotic Hepatitis B patients: risk stratified using the PAGE-B score to guide surveillance eligibility based on age, sex, and geographic location
- Non-cirrhotic MASLD (MASH): surveillance is not currently recommended due to insufficient incidence to meet cost-effectiveness thresholds (~1% annual incidence required per modeling studies)
- Hepatitis C with SVR: surveillance should continue in cirrhotic patients despite viral eradication, as risk is reduced but not eliminated
Diagnostic Criteria Evolution:
- 2005 AASLD guidelines: relied on atypical vascular pattern and AFP alone — limited sensitivity and specificity
- Key radiologic advance: addition of arterial enhancement + washout as diagnostic features (described ~2003)
- Current standard: LI-RADS category 5 (LR-5) — arterial phase hyperenhancement with washout appearance
- This has provided a more consistent, validated diagnostic framework over the past 10–15 years
3. Specific Clinical Data, Statistics, and Study Results Cited
Global Epidemiology (GLOBOCAN 2022):
- Liver cancer: 6th most common solid tumor worldwide by incidence
- 3rd leading cause of cancer mortality globally
- Incidence approximates mortality in many Asian and Sub-Saharan African countries, reflecting inadequate early detection infrastructure
- Strong male predominance across all geographic regions
U.S. Epidemiology (SEER Database, 2025 estimates):
- Estimated ~42,000 new HCC cases and ~30,000 deaths in 2025
- U.S. incidence peaked in 2012, now declining (attributed to HCV treatment advances)
- Mortality has been rising but is now plateauing
- 5-year survival rate: 22% — highlighting the critical need for early detection
Etiology Trends (U.S. Liver Transplant Waitlist Data):
- Hepatitis C–related HCC listings have dramatically declined since ~2012
- Alcohol-associated liver disease is now the leading cause for transplant listing
- MASLD/MASH + unknown etiology collectively represent the second major emerging cause
Shanghai Randomized Controlled Trial (Hepatitis B population, n=20,000):
- Patients randomized to AFP + ultrasound surveillance vs. no surveillance
- Surveillance group: 86 cases detected, with 37% reduction in HCC mortality
- Early-stage detection sensitivity: 71%; specificity: 92.5%
- Represents the only Level I evidence for HCC surveillance reducing mortality
Meta-Analysis of Ultrasound Performance (Singal et al., 2018):
- Ultrasound alone sensitivity: ~45%
- Ultrasound + AFP sensitivity: ~63%; specificity: ~90%
- These figures have remained consistent in subsequent analyses
Systematic Review — Surveillance and Survival Outcomes (2014–2020):
- 59 studies; 145,000 patients
- Surveillance associated with:
- Increased early-stage detection
- Higher rates of curative therapy receipt
-